Thelansis

 Graft vs Host Disease (GVHD) is a condition in transplant rejection where the immune cells from the donor launch an immune attack against the recipient's tissues, perceiving them as foreign. This immune reaction primarily involves the donor's T cells (the graft) targeting and damaging the recipient's healthy cells (the host). GVHD has traditionally been categorized based on the onset time, with a cutoff point of 100 days following the transplant. The National Institutes of Health (NIH) has further classified GVHD based on recognized clinical manifestations into the following subtypes: 1.        Acute classic GVHD: This form appears within the first 100 days after transplantation and displays the typical clinical features of acute GVHD. 2.        Persistent, recurrent, or late-onset acute GVHD: This variation presents with the classic features of acute GVHD but occurs more than 100 days after the transplant. 3. ...

  Graft vs Host Disease (GVHD) is a pattern of transplant rejection in which donor immune cells mount an immune response against host tissues. GVHD occurs when the donor’s T cells (the graft) view the patient’s healthy cells (the host) as foreign and attack and damage them. Graft-versus-host disease can be mild, moderate or severe. In some cases, it can be life-threatening. The incidence of chronic GVHD ranges from 6% to 80%. GVHD is considered one of the main causes of morbidity and mortality after HCT; more than 10% of patients will die from this complication. Thelansis’s “Graft vs Host Disease (GVHD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Graft vs Host Disease (GV...